eatris European infrastructure for translational medicine

Want to accelerate your ATMP development towards the clinic?

Advanced Therapies are at the frontier of novel therapeutic approaches for many disease types, but the process of translating them into clinical use is difficult to navigate.

The EATRIS ATMP Platform offers access to multiple GMP, preclinical and clinical facilities including patient cohorts and regulatory guidance for your ATMP product development.

What can EATRIS offer the ATMP developer?

1. 46 state-of-the-art centres with expertise covering all classes of ATMPs
2. Clinical expertise and access to patients
3. Cutting-edge technologies including:
   - Design and Production of Advanced Therapy Medicinal Products (GMP)
   - Innovative Pre-clinical tools to assess safety and efficacy of Cell and Gene Therapy Products including tailored animal models
   - Imaging facilities for in vivo animal studies - cell tracking
   - Characterisation and monitoring of treatment-related immune responses and immunogenicity evaluation
   - Regulatory expertise to develop to guide the product development process

What services can we provide?

Expertise in cell therapy and genome editing products in targeted cells and tissues (e.g., base editing, prime editing, talens, zinc-finger nucleases, CRISPR).	Expertise in novel RNA-based therapeutics	Expertise in gene delivery vehicles using next generation AAV or other recombinant vectors
Expertise in upscaling and GMP product development of advanced therapies in cell and gene therapies and vector production	Advanced technologies for disease specific research including cancer organoids, organ on a chip to test responses to different ATMPs	Multimodal Imaging approaches to track cells to measure biodistribution and efficacy of immunotherapies including nanoparticle approaches, PET-CT, PET-MRI
In vivo Imaging Technologies to Monitor the Immune System - Mass Cytometry Imaging (MCI), PET-CT, PET-MRI, US modalities for studies of the immune system response	Access to 3D culture systems; patient-derived organoids; patient-derived xenografts, Spheroids and Multifluidic Devices for Immune surveillance in TME for ATMP products	Pre-clinical in vivo validation in disease specific animal models including primates
Pre-clinical evaluation of ATMP immunogenicity, efficacy and toxicology	Regulatory Services- Scientific Advice, TPP and IMPD development	Clinical trial centres for phase I/II studies in conjunction with a university medical centre to foster interaction between clinicians and specialist scientists

Looking for something else?

Contact David Morrow, Senior Scientific Programme Manager: davidmorrow@eatris.eu

Or find us online:

eatris.eu EatrisEric eatris-eric EATRIS-ERIC EATRIS.ERIC